Schizophrenia is considered one of the leading psychiatric disorders due to its incidence of 1% in the general population. Due to its many presentations it can not be defined as a single entity, but rather a disorder with heterogeneous genetic, neurobiological, environmental and social background, manifested by a series of cognitive, behavioral and emotional deviations, which speaks in favor that there are no two identical clinical presentations of schizophrenia. Schizophrenia is also a chronic disorder, requiring long-term care. Because of its long duration, insufficiently known etiology, behavioral changes and alterations of psychic functions, and the fact that it most commonly occurs during late adolescence, schizophrenia significantly impairs work and social functionality of the affected individual and has a negative impact on both the quality of life of the patient and the patient’s family, health system and society in general. What has recently caught the field’s attention is the presence of comorbid somatic diseases in patients with schizophrenia who have not yet been adequately diagnosed and treated. One of the most common and severely debilitating is the metabolic syndrome. It is a syndrome consisting of a series of metabolic abnormalities that result from a number of factors, such as: inadequate nutrition, lack of physical activity and smoking, the effects of the psychotic disorder itself, as well as the potentially adverse effects of antipsychotics in patients with schizophrenia. The term metabolic syndrome implies abdominal or central obesity, hypertriglyceridemia with lowered HDL-cholesterol, hypertension and hyperglycemia. If these metabolic disorders occur at the same time, the patient is at increased risk of cardiovascular, cerebrovascular disease and the development of type II diabetes. Cardiovascular disease, along with suicide, is the most important cause of mortality in patients with schizophrenia. Metabolic abnormalities are known to be associated with chronic course of the disorder and long-term administration of certain antipsychotics. However, there is a possibility that metabolic parameters are impaired at the outset of the disorder, that is, when the first diagnosis of schizophrenia is made. That is in fact the main hypothesis of this research. The aim of the study was to prospectively examine and analyze the values of the aforementioned metabolic parameters and to determine if the metabolic syndrome is present in 30 subjects with the first episode of schizophrenia. Those values were compared with those of other 30 subjects, who were previously diagnosed with schizophrenia and another 30 subjects, who were not diagnosed with the disorder (healthy individuals). This study was conducted at the Clinic for Psychiatry of the UHC Sestre milosrdnice. For the purpose of the study, laboratory values of serum lipids and glucose, anthropometric measures, and the existence of nicotine dependence in the subjects were analyzed. The study did not confirm the hypothesis that metabolic parameters are abnormal at the very beginning of the disorder, when the diagnosis of schizophrenia is made for the first time in patients’ lives. The present parameters do not meet the diagnostic criteria for the diagnosis of metabolic disorder in patients with the first episode of schizophrenia.